Adverse Drug Reactions - Part I
COURSE NUMBER: 536
Michaell A. Huber, DDS
Credit Hours:
3 Hour(s)
SHARE
Adverse drug reactions (ADRs) may be characterized as (1) “on-target”, (2) “off-target”, (3) cytotoxic reactions, (4) immune-mediated reactions, and (5) idiosyncratic reactions.1; This course discusses common “on-target,” (2) “of...
(Use this feature to create assignments for your students and staff.)
Overview
Adverse drug reactions (ADRs) may be characterized as (1) “on-target”, (2) “off-target”, (3) cytotoxic reactions, (4) immune-mediated reactions, and (5) idiosyncratic reactions.1; This course discusses common “on-target,” (2) “off-target,” and (3) cytotoxic reactions immune-mediated and idiosyncratic ADRs related to the top 200 drugs dispensed by U.S. community pharmacies in 2008 to inform and raise the level of awareness of oral healthcare providers of the spectrum of potential ADRs affecting their patient cohort. A discussion of less common ADRs that relate to dental therapeutics and/or manifest in the head and neck area is also provided.
Please note that this is Part I of a two-part series. [Adverse Drug Reactions – Part II] (https://www.dentalcare.com/en-us/ce-courses/ce537) discusses common immune-mediated and idiosyncratic ADRs related to the top 200 drugs dispensed by U.S. community pharmacies in 2008, and less common ADRs that relate to dental therapeutics and/or manifest in the head and neck area.
Intended Audience:
Dentists, Dental Hygienists, Dental Assistants, Dental Students, Dental Hygiene Students, Dental Assisting Students
Date Course Online:
Jul 1, 2017
Last Revision Date:
Feb 17, 2026
Course Expiration Date:
Feb 16, 2029
Cost:
Free
Method:
Self-instructional
AGD Subject Code(s):
10
Technical Requirements:
Stable internet connection and the latest version of browser and device software are recommended.
Learning Objectives
Upon completion of this course, the dental professional should be able to:
- Discuss in general terms the approval process of new drugs and their limitations as they relate to ADRs.
- Discuss “on-target,” “off-target,” and cytotoxic mechanisms of ADRs.
- Develop a clinical frame of reference related to ADRs.
- Discuss the spectrum of potential ADRs affecting the head and neck area and various organ systems associated with dental therapeutics and the top 200 drugs dispensed by U.S. community pharmacies.
Disclaimers
P&G is providing these resource materials to dental professionals. We do not own this content nor are we responsible for any material herein.
Participants must always be aware of the hazards of using limited knowledge in integrating new techniques or procedures into their practice. Only sound evidence-based dentistry should be used in patient therapy.
Note: Registration is required to take test.
Submission Information
Academy of General Dentistry (AGD) Submission For credit transfers to appear in your AGD account in real time, make sure to add your AGD membership number in the field provided on the “Share Your Test Score” page.
CE Broker For all states that use CE Broker for licensure, “proof of completions” are electronically reported the first of every month. If a course was taken in November, the “proof of completion” will be submitted the beginning of December.
Recognition
Approved PACE Program Provider
THE PROCTER & GAMBLE COMPANY
Nationally Approved PACE Program Provider for FAGD/MAGD credit.
Approval does not imply acceptance by any regulatory authority or AGD endorsement.
8/1/2021 to 7/31/2027
Provider ID# 211886
AADH Approved Program Provider
Procter and Gamble is designated as an approved provider by the American Academy of Dental Hygiene, Inc. #AADHPGC (January 1, 2026 - December 31, 2027). Approval does not imply acceptance by a state or provincial Board of Dentistry. Licensee should maintain this document in the event of an audit.
(Use this feature to create assignments for your students and staff.)